Wednesday, October 02, 2019 8:13:04 PM
I rather look at it this way...
Fundamentals matter alot, and price action matters as well.
If I own MRKR at a core of 4.25,its alot better position to be in than owning it at 6.25.
If I can watch the price action patterns and ride the waves up and down to the lowest targets,I can buy the bargain lows and take profit at target tops, whats so hard to understand. Yes, some day if the science wins the contest and we have a great investment thats what holding a core is waiting for. but the portion of trading shares can make some money riding the waves in the mean time.
I went from starting a position at 6.25 to being almost finished with a core now at 4.75
because I used the TA analysis to find trade targets up and down.
Both things really matter. the science success, and buying at the best bargain lows. and taking some profit along the way up and down.
Fundamentals matter alot, and price action matters as well.
If I own MRKR at a core of 4.25,its alot better position to be in than owning it at 6.25.
If I can watch the price action patterns and ride the waves up and down to the lowest targets,I can buy the bargain lows and take profit at target tops, whats so hard to understand. Yes, some day if the science wins the contest and we have a great investment thats what holding a core is waiting for. but the portion of trading shares can make some money riding the waves in the mean time.
I went from starting a position at 6.25 to being almost finished with a core now at 4.75
because I used the TA analysis to find trade targets up and down.
Both things really matter. the science success, and buying at the best bargain lows. and taking some profit along the way up and down.
Recent MRKR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 09:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:30:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:08:49 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/20/2026 08:07:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:05:49 PM
- Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results • GlobeNewswire Inc. • 03/18/2026 09:31:30 PM
- Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 09:06:45 PM
- Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology • GlobeNewswire Inc. • 01/26/2026 12:00:00 PM
- Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer • GlobeNewswire Inc. • 01/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:15 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/17/2025 09:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:20:47 PM
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:29:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2025 12:36:59 PM
- Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors • GlobeNewswire Inc. • 11/05/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:09:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:03:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 09:54:39 PM
- Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting • GlobeNewswire Inc. • 11/03/2025 02:15:00 PM
- Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program • GlobeNewswire Inc. • 10/06/2025 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 11:30:37 AM
